Administrative Procedures Organized in Lawsuits That Claim Zantac Caused Cancer

Thousands of plaintiffs may file lawsuits against Sanofi when informed of the results of the first bellwether trial

Monday, September 28, 2020 - In a recent development regarding the first Zantac cancer trial, a federal judge has organized a group of attorneys to lead 230 plaintiffs. South Florida Caribean News reported; "The team comprises co-lead counsels, the plaintiff's liaison counsel, the plaintiff's steering committee, and a leadership development committee. The court hopes that the team will count on its diversity as the case goes forward." The attorneys are "a diverse group of minorities," both men and women, young and old with the intent of reflecting the diversity of the pool of plaintiffs. The judge hopes that the team will bring a combination of youth and experience to the proceedings as well.

Zantac is Sanofi's flagship medicine and the world's best-selling heartburn and acid reflux reliever. In February of 2020, the company was accused by plaintiffs organized into multidistrict litigation (MDL) in the Southern District of Florida, of concealing the carcinogenic nature of Zantac, (ranitidine). Before its company and FDA recall in early 2020, Zantac was used by over 15 million people every year and earned the company over one billion dollars in profits. Zantac (ranitidine) is sold over the counter and prescribed by doctors. Zantac is an H2 blocker drug. Patient.Info explains, "H2 blockers are a group of medicines that reduce the amount of acid produced by the cells in the lining of the stomach. They are also called 'histamine H2-receptor antagonists' but are commonly called H2 blockers. They include cimetidine, famotidine, nizatidine, and ranitidine (Zantac), and have various brand names."

Online drug testing pharmacy Valisure found Zantac to contain levels of NDMA, a well-known carcinogen that was unacceptably high and likely to cause cancer. Valisure found levels of NDMA thousands of times greater than the 96 ng per tablet that the FDA used as an acceptable benchmark. Valisure filed a citizen petition immediately with the FDA demanding the drug ranitidine be recalled from the market. Sanofi immediately withdrew Zantac and the FDA followed suit on April 1, 2020, to include all manufacturers of ranitidine to recall the drug as well.

Personal lawsuits accuse the Sanofi, the maker of Zantac, of having the responsibility to know and to inform their consumers of the cancer risks of ranitidine. Zantac is accused of causing a variety of cancers with the list growing every day. At last count, lawsuits have been filed that claim using Zantac has caused cancer of the stomach, bladder, esophagus, prostate, colon, intestinal, and breast. Regular Zantac users that have been diagnosed with cancer are urged to seek counsel from a Zantac Cancer Lawyer to see if they qualify to file a claim. Individual cases are being in the process of being organized into groups called multidistrict litigation (MDL) to streamline administrative court proceedings and also to ferret out the facts about the complex science regarding NDMA and Zantac causing cancer for which they are accused.

More Recent Heartburn MedicineLawsuit News:

• Zantac Cancer Trials Are In Discovery To Begin In October 2022 | 7/19/2022
• Zantac Cancer Lawsuits Could Hinge On The Validity of Ranitidine Testing Methods | 7/11/2022
• Zantac Cancer Bellwether Trials In California Could Set The Stage For A Global Settlement Offer | 7/5/2022
• The FDA Recommended Protein Pump Inhibitor Drugs Like Prilosec And Nexium That May Damage Health More Than Zantac | 6/23/2022
• Truck Drivers, Firefighters, and Police Officers May Have Taken More Zantac Than People In Other Occupations | 6/20/2022
• Scientists Are Expected To Confirm That Ranidine Causes Gastrointestinal Cancer With Slam Dunk Testimony | 6/9/2022
• Scientific Hearings Will Start This September To Interview Zantac Cancer Expert Witnesses | 5/19/2022
• A Whistleblower Scientist Working For A Chinese Company Thinks NDMA Contamination Started In China | 5/12/2022
• Valisure's String Of Stunning Success Casts Doubt On The FDAs Ability To Police The Health Care Market | 5/2/2022
• Zantac Testing Accusations Heat Up With FDA Investigation Of Online Prescription Drug Testing Lab | 4/25/2022
• Study Finds Ranitidine Degrades Into 10,000 Nanograms of NDMA When Introduced To Simulated Stomach Conditions | 4/6/2022
• Potential Zantac Expert Witnesses Are Being Questioned By Zantac Defense Attorneys | 3/31/2022
• The FDA Requires That Drug Companies Regularly Test Ranitidine And Other Drug For NDMA | 3/24/2022
• Update: Where The Zantac Cancer Multidistrict Litigation (MDL) Stands Today | 3/12/2022
• Zantac Cancer Plaintiffs Look To The First Trial In October In Alameda California | 3/11/2022
• Zantac Cancer Plaintiffs Have Until June 30 To Finalize Their Claim | 3/7/2022
• Zantac Bellwether Trials May Focus On Ranitidine Testing Methods That Could Cause NDMA To Accelerate | 3/1/2022
• Valisure LLC's Motivations And Ranitidine Testing Methods May Not Be Scrutinized Before Trial | 2/24/2022
• Zantac Lawsuits May Go To Trial In California In October Of This Year | 2/18/2022
• Sanofi's History Of Reprehensible Corporate Behavior May Bolster Zantac Cancer Lawsuits | 2/10/2022

Lawyers for Zantac Heartburn Medicine Lawsuits

OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.